ClinicalTrials.gg
Active, not recruitingNCT06513234Updated Nov 3, 2026

Combination of Orelabrutinib and Obinutuzumab in Untreated Marginal Zone Lymphomas

A Phase 2 interventional study of Orelabrutinib and obinutuzumab in Marginal Zone Lymphoma, sponsored by Institute of Hematology & Blood Diseases Hospital, China. Active, not recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Institute of Hematology & Blood Diseases Hospital, China · Phase 2, Interventional, and Treatment

How we know

Updated Nov 3, 2026Now Active, not recruitingPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
74
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies testing orelabrutinib in Lymphoma, B-Cell, Marginal Zone — 17 open to participants now, 21 under way, 1 of them phase 3. orelabrutinib · Lymphoma, B-Cell, Marginal Zone.

Planned enrollment
7th of 21
74 · median 51
Started
2024
with 6 others
Phase 2
17 of 21
13 open now
Primary completion
2027-06
later than 6 of 20 live
Registered
5th of 21
by date
Lead sponsor
2 of 21
Institute of Hematology & Blood Diseases Hospital, China

Among the 21 studies testing orelabrutinib in Lymphoma, B-Cell, Marginal Zone, this one is the 7th largest by planned enrollment, is one of 7 that started in 2024, is one of 17 in phase 2, reaches primary completion later than 6 of the 20 other live ones, and was the 5th registered.

Lymphoma, B-Cell, Marginal Zone

877 studies on the registry are indexed under Lymphoma, B-Cell, Marginal Zone; 113 are open to participants now.

Browse Lymphoma, B-Cell, Marginal Zone studies →

Open to participants now

17 of the 21 studies testing orelabrutinib in Lymphoma, B-Cell, Marginal Zone are open now, in 1 country. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 17 open studies →

Where they have run

About orelabrutinib

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 93 Lymphoma, B-Cell, Marginal Zone studies recruiting now, 78 (84%) set no upper age limit and 7 (8%) stop at 75 or younger; 10 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing orelabrutinib in Lymphoma, B-Cell, Marginal Zone, or all of them as a file.
02

Study summary

This is a prospective single arm phase II study, and the purpose of this study is to evaluate the safety and efficacy of orelabrutinib combined with obinutuzumab a in untreated marginal zone lymphoma. It is planned to recruit 45 patients. The primary endpoint is the complete remission rate at 12 months.

Read the detailed description

Marginal zone lymphomas (MZL) are a type of lymphoma that originates from the marginal zone tissue of the lymphoid follicles (Mucosa-associated lymphoid tissue, MALT), and include three subtypes: MALT lymphoma, nodal MZL, and splenic MZL. For patients with marginal zone lymphoma who have indications for systemic anti-tumor treatment, therapeutic options include rituximab monotherapy or more intensive immunochemotherapy regimens in combination with bendamustine, chlorambucil, CHOP regimen (cyclophosphamide, vincristine, doxorubicin, prednisone), etc.

This is a prospective, phase II, single-arm clinical study to initially explore the efficacy and safety of Orelabrutinib combined with obinutuzumab in patients with previously untreated marginal zone lymphoma. The patients will be treated with 6 cycles of OG regimen. Patients with CR/PR after 6 cycles of OG treatment will be treated with 18 cycles of single-agent orelabrutinib regimen.

03

Conditions studied

  • Marginal Zone Lymphoma

Keywords

  • Marginal Zone Lymphomas
  • orelabrutinib
  • obinutuzumab
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    • Age ≥18 years, gender unrestricted;

      • Histopathologically confirmed CD20-positive marginal zone lymphoma including MALT, SMZL, NMZL;
      • MZL that has progressed, recurred, or is unsuitable for local treatment after previous local therapy (local treatments include surgery, radiotherapy, Helicobacter pylori treatment, treatment);
      • performance status score of 0-2.
      • Major organ functions meet the following criteria: a) Complete blood count: ≥1.5×10\^9/L, ≥75×10\^9/L, ≥75g/L; if accompanied by bone marrow involvement, absolute neutrophil count ≥1.0×10\^9/L, platelets ≥50×10\^9/L, hemoglobin ≥50g/L; b) Blood biochemistry: Total ≤1.5 times the (ULN), or ALT ≤2 times ULN; serum creatinine ≤1.5 times ULN; serum amylase ≤ULN; c) Coagulation function: (INR) ≤1.5 times ULN.
      • ≥3 months;
      • Voluntarily sign a written form before the trial screening.

Exclusion criteria

Exclusion Criteria:

  • Currently or previously having other malignant tumors, unless radical treatment has been performed and there is evidence of no recurrence or within the last 5 years;
  • Lymphoma involving the central nervous system or transforming into a higher grade;
  • Having uncontrollable or significant cardiovascular diseases, including: a) (NYHA) class II or above congestive heart failure, unstable angina, myocardial infarction within 6 months before the first administration of the study drug, or arrhythmias requiring treatment at the time of screening, with a (LVEF) \<50%; b) Primary cardiomyopathy (such as dilated cardiomyopathy, hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, restrictive cardiomyopathy, unclassified cardiomyopathy); c) A history of prolongation, or a QTc interval >470ms in females and >450ms in males during the screening period; d) Subjects with symptomatic or medication-requiring coronary artery heart disease; e) Subjects with difficult-to-control hypertension (despite lifestyle improvements and the use of reasonable, tolerable, and adequate doses of one or three or more antihypertensive drugs [including diuretics] for more than 1 month, blood pressure is still not at the standard, or it is only effectively controlled when taking four or more antihypertensive drugs).
  • Active bleeding within 2 months before screening, or currently taking anticoagulant drugs, or the investigator believes there is a definite bleeding tendency;
  • Active infection or uncontrolled (positive for HBsAg and/or HBcAb with positive HBV DNA titer), positive for Ab, /AIDS, or other serious infectious diseases.
  • Any other conditions deemed unsuitable for participation in this trial by the investigator.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
74 participants (estimated)

Study arms

  • Experimental
    OG

    6 cycles of OG regimen. Patients with CR/PR after 6 cycles of OG treatment will be treated with 18 cycles of single-agent orelabrutinib regimen. Orelabrutinib 150mg QD

    Drug: Orelabrutinib and obinutuzumab

Interventions

06

What researchers measure

Primary outcomes

  1. the complete response rate

    CRR is defined as the proportion of patients with a response of CR

    Time frame: At 12 months.

Secondary outcomes

  1. CRR

    CRR is defined as the proportion of patients with a best response of CR

    Time frame: At the end of induction therapy(6cycles). 28days/cycle

  2. ORR

    The ORR is defined as the proportion of patients with a response of CR

    Time frame: At 12 months.

  3. BOR

    The BOR is defined as the proportion of patients with a best response of CR or PR

    Time frame: At 12 months.

  4. 2 years progression-free survival

    Progression free survival (PFS) is defined as the time from registration to the first occurrence of progression or relapse as assessed by the investigator, or death from any cause. PFS for patients without disease progression, relapse, or death will be censored at the time of the last tumor assessment.

    Time frame: From date of signing the informed consent until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years

  5. 2 years overall survival

    Overall survival is defined as the period from the induction registration to death from any cause. Patients who have not died until the time of the analysis will be censored at their last contact date.

    Time frame: From date of signing the informed consent until the date of death from any cause, whichever came first, assessed up to 2 years]

  6. TTR

    TTR is defined as the time from registration to the first response.

    Time frame: Up to 2 years

  7. Duration of Response (DOR)

    Duration of response as defined as the period from the first response (at least PR) to treatment until evidence of disease progression, relapse or death of any cause. Patients alive without progression and relapse will be censored at the latest tumor assessment date or the stopping date.

    Time frame: Up to 2 years

  8. The occurrence of adverse events and serious adverse events

    Adverse events will be graded by the investigator according to the NCI-CTCAE Version 5.

    Time frame: One month after discontinuation of treatment

07

Study locations

1 site
08

References and documents

Publications

  • Sharp J, Shana'ah AY, Voorhees TJ, Bond DA, Sawalha Y, Sigmund A, Hanel W, Sehgal L, Alinari L, Baiocchi R, Maddocks K, Jones D, Christian B, Epperla N. Resistance Mechanism for Zanubrutinib in Marginal Zone Lymphoma. J Natl Compr Canc Netw. 2025 Jun 23;23(7):e257045. doi: 10.6004/jnccn.2025.7045. PubMed 40550489 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Jun 2027, 35 months after the start.

Of 97 non-industry phase 2 interventional studies under Lymphoma, B-Cell, Marginal Zone, half reached primary completion within 73 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 117. This study's planned 35 months is below that.

Counting every sponsor, half of 113 studies reached it within 69 months; a quarter within 38 and three quarters within 110.

Primary completion moved once since we started tracking on Sep 25, 2026: Jun 2026 → Jun 2027, on Nov 3, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 1, 2024
First posted
Jul 22, 2024
StartActual
Jul 11, 2024
Primary completionEst.
Jun 21, 2027was Jun 2026
CompletionEst.
Jun 21, 2029
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Nov 3, 2026
Primary completion
Jun 21, 2026→Jun 21, 2027
Nov 3, 2026
Enrollment
45→74
Nov 3, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 40550489 ↗
Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    Recruiting→Active, not recruiting
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 40550489 ↗
    Primary completion Jun 21, 2026→Jun 21, 2027
    Enrollment 45→74
    + 4 other changes: verification date, contact details, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06513234
Responsible party
Sponsor
First posted
Jul 22, 2024
Start date
Jul 11, 2024
Primary completion
Jun 21, 2027 (estimated)
Completion
Jun 21, 2029 (estimated)
Last update
Nov 3, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Orelabrutinib · Obinutuzumab

Start the discussion